Drug profile · INN
becaplermin
GEMESIS
becaplermin (GEMESIS) is a platelet-derived growth factor receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Drug details — becaplermin
- US status
- approved
- Class
- Dermatologicals (D03)
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
becaplermin (GEMESIS) is a platelet-derived growth factor receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Platelet-derived growth factor receptor agonist
Primary target: Platelet-derived growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is becaplermin?
becaplermin (GEMESIS) is a platelet-derived growth factor receptor agonist. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for becaplermin?
GEMESIS is a marketed brand name for becaplermin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of becaplermin?
becaplermin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.